Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00260741 · ClinicalTrials.gov registry record · Phase 1
Cannabis for Spasticity in Multiple Sclerosis
A Phase 1 study, sponsored by Center for Medicinal Cannabis Research.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00260741 is a Phase 1 study that was terminated before completion, run by Center for Medicinal Cannabis Research. The registered enrollment target is 60 participants.
The verdict
NCT00260741, a Phase 1 study, was terminated before completion, sponsored by Center for Medicinal Cannabis Research.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary progressive multiple sclerosis.
Interventions
- DRUG Smoked Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00260741
The ClinicalTrials.gov registry entry for NCT00260741 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Center for Medicinal Cannabis Research, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Smoked Cannabis is the first listed.
NCT00260741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00260741 about?
NCT00260741 is a clinical study titled "Cannabis for Spasticity in Multiple Sclerosis". The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary pro...
What is the current status of trial NCT00260741?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2003-03. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00260741?
The interventions under investigation include: Smoked Cannabis (DRUG).
Who is sponsoring clinical trial NCT00260741?
This trial is sponsored by Center for Medicinal Cannabis Research, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.